Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Glucose Measurements - Database and Calibration Compilation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with and without diabetes including pregnant women~Exclusion Criteria:~* Subject under 18 years of age~* Subjects not able to understand provided information~* Subjects without measuring sites~* Subjects with rash or wound on measuring sites~* Subjects with stained fingers, such a oil or nicotine~* Subjects not capable of holding arm/hand steadily on probe~* Subjects with thrombosis in arm/hand

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- OUH protocol (Type: EXPERIMENTAL): The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~* Optical Coherence Tomography (OCT)~* Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2.
- Home 1 protocol (Type: EXPERIMENTAL): Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference.
- Home 2 protocol (Type: EXPERIMENTAL): Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference.

Based on this trial design, predict the completion outcome and termination type (if applicable).